Ruxolitinib cream, applied twice daily, quickly reduced itch in people with mild to moderate eczema. The cream started working within 12 hours and continued to improve itch symptoms over 8 weeks. The stronger version (1.5%) worked better than the weaker version (0.75%) and both worked better than the placebo cream.
-
Editor's Picks January 2023
Editor's Picks January 2023
nan
DOI: 10.1111/jdv.18732
None
•
1,200 participants
•
2023
•
0 citations
Key insights related to Opzelura from this study:
-
What is this paper about?
-
What populations did the authors study?
1200 patients. With mild to moderate eczema. Patients are adolescents and adults.
-
What did the authors find?
Analyzing metric: Itch NRS (≥ 2 point reduction).
Findings show: Invervention leads to 13.1% (1.5% cream).
Resulting in: Twice as many patients using the stronger ruxolitinib cream experienced significant itch reduction within 12 hours compared to placebo.
Analyzing metric: Itch NRS (≥ 4 point reduction).
Findings show: Invervention leads to statistically significant improvement.
Resulting in: Patients using ruxolitinib cream experienced major itch reduction within 36 hours. -
What conclusions can we draw?
nan
Did this article interest you?
As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.
Ready for better skin health?
At Lemma Health, we provide evidence-based skin care. Access dermatologists in all 50 states. Appointments available within 3 days. Receive your medications delivered. Get ongoing 24/7/365 support. Coordinate your care across specialties.